ELIZABETH GABELMAN: Open Payments
NPI 1598528077 · GLEN BURNIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,874 in 90 payments from 22 companies in 2025. Trend: 2023 $0 · 2024 $1,179 · 2025 $1,874
Food & beverage: $1,874
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 25 | $588 |
| Lilly USA, LLC | 11 | $232 |
| ABBVIE INC. | 11 | $171 |
| AstraZeneca Pharmaceuticals LP | 5 | $105 |
| Dexcom, Inc. | 5 | $94 |
| PFIZER INC. | 5 | $90 |
| Merck Sharp & Dohme LLC | 3 | $70 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $68 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $60 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $60 |
Products named: Rybelsus, MOUNJARO, Ozempic, Wegovy, VRAYLAR, Dexcom G6 Transmitter, GARDASIL 9, JARDIANCE.
Industry payments across MD — which companies pay providers there.
